The Phospholamban Journey 4 Decades After Setting Out for Ithaka.
作者信息
Kranias Evangelia G, Hajjar Roger J
机构信息
From the Department of Pharmacology and Cell Biophysics, University of Cincinnati College of Medicine, OH (E.G.K.); and Cardiovascular Research Center, Department of Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY (R.J.H.).
出版信息
Circ Res. 2017 Mar 3;120(5):781-783. doi: 10.1161/CIRCRESAHA.116.310007.
Abstract
摘要
相似文献
1
The Phospholamban Journey 4 Decades After Setting Out for Ithaka.
Circ Res. 2017 Mar 3;120(5):781-783. doi: 10.1161/CIRCRESAHA.116.310007.
2
Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban.
Science. 2003 Feb 28;299(5611):1410-3. doi: 10.1126/science.1081578.
3
Sarcoplasmic reticulum Ca-ATPase-phospholamban interactions and dilated cardiomyopathy.
Biochem Biophys Res Commun. 2004 Oct 1;322(4):1214-22. doi: 10.1016/j.bbrc.2004.07.164.
4
Phospholamban: a crucial regulator of cardiac contractility.
Nat Rev Mol Cell Biol. 2003 Jul;4(7):566-77. doi: 10.1038/nrm1151.
5
Deception in simplicity: hereditary phospholamban mutations in dilated cardiomyopathy.
Biochem Cell Biol. 2015 Feb;93(1):1-7. doi: 10.1139/bcb-2014-0080. Epub 2014 Dec 1.
6
Alterations of phospholamban function can exhibit cardiotoxic effects independent of excessive sarcoplasmic reticulum Ca2+-ATPase inhibition.
Circulation. 2009 Jan 27;119(3):436-44. doi: 10.1161/CIRCULATIONAHA.108.783506. Epub 2009 Jan 12.
7
Phospholamban: a key determinant of cardiac function and dysfunction.
Arch Mal Coeur Vaiss. 2005 Dec;98(12):1239-43.
8
Phospholamban and cardiac contractility.
Ann Med. 2000 Nov;32(8):572-8. doi: 10.3109/07853890008998837.
9
A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy.
Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1388-93. doi: 10.1073/pnas.0510519103. Epub 2006 Jan 23.
10
Ca2+/calmodulin-dependent protein kinase modulates cardiac ryanodine receptor phosphorylation and sarcoplasmic reticulum Ca2+ leak in heart failure.
Circ Res. 2005 Dec 9;97(12):1314-22. doi: 10.1161/01.RES.0000194329.41863.89. Epub 2005 Nov 3.
引用本文的文献
1
Genetic landscape of phospholamban cardiomyopathies.
Front Cell Dev Biol. 2025 Jun 10;13:1626242. doi: 10.3389/fcell.2025.1626242. eCollection 2025.
2
Calcium-dependent levels of phospholamban pentamer in native heart membranes reflect interactions of monomers with calcium-free SERCA2a.
Arch Biochem Biophys. 2025 Jul;769:110432. doi: 10.1016/j.abb.2025.110432. Epub 2025 Apr 20.
3
A novel role for phospholamban in the thalamic reticular nucleus.
Sci Rep. 2024 Mar 16;14(1):6376. doi: 10.1038/s41598-024-56447-x.
4
Phospholamban R14del disease: The past, the present and the future.
Front Cardiovasc Med. 2023 Apr 18;10:1162205. doi: 10.3389/fcvm.2023.1162205. eCollection 2023.
5
Exercise Causes Arrhythmogenic Remodeling of Intracellular Calcium Dynamics in Plakophilin-2-Deficient Hearts.
Circulation. 2022 May 10;145(19):1480-1496. doi: 10.1161/CIRCULATIONAHA.121.057757. Epub 2022 May 1.
6
A kink in DWORF helical structure controls the activation of the sarcoplasmic reticulum Ca-ATPase.
Structure. 2022 Mar 3;30(3):360-370.e6. doi: 10.1016/j.str.2021.11.003. Epub 2021 Dec 6.
7
An mRNA assay system demonstrates proteasomal-specific degradation contributes to cardiomyopathic phospholamban null mutation.
Mol Med. 2021 Sep 8;27(1):102. doi: 10.1186/s10020-021-00362-8.
8
Structural basis for allosteric control of the SERCA-Phospholamban membrane complex by Ca and phosphorylation.
Elife. 2021 May 12;10:e66226. doi: 10.7554/eLife.66226.
9
Chronic cardiac structural damage, diastolic and systolic dysfunction following acute myocardial injury due to bromine exposure in rats.
Arch Toxicol. 2021 Jan;95(1):179-193. doi: 10.1007/s00204-020-02919-8. Epub 2020 Sep 26.
10
Genetic basis and molecular biology of cardiac arrhythmias in cardiomyopathies.
Cardiovasc Res. 2020 Jul 15;116(9):1600-1619. doi: 10.1093/cvr/cvaa116.
本文引用的文献
1
Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy.
Nat Commun. 2015 Apr 29;6:6955. doi: 10.1038/ncomms7955.
2
The structural basis for phospholamban inhibition of the calcium pump in sarcoplasmic reticulum.
J Biol Chem. 2013 Oct 18;288(42):30181-30191. doi: 10.1074/jbc.M113.501585. Epub 2013 Aug 31.
3
Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy.
Eur J Heart Fail. 2012 Nov;14(11):1199-207. doi: 10.1093/eurjhf/hfs119. Epub 2012 Jul 20.
4
Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome.
Circ Res. 2012 Jun 8;110(12):1646-60. doi: 10.1161/CIRCRESAHA.111.259754.
5
Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy.
Circulation. 2009 Mar 10;119(9):1241-52. doi: 10.1161/CIRCULATIONAHA.108.783852. Epub 2009 Feb 23.
6
A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy.
Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1388-93. doi: 10.1073/pnas.0510519103. Epub 2006 Jan 23.
7
Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human.
J Clin Invest. 2003 Mar;111(6):869-76. doi: 10.1172/JCI17892.
8
Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban.
Science. 2003 Feb 28;299(5611):1410-3. doi: 10.1126/science.1081578.
9
Phospholamban: protein structure, mechanism of action, and role in cardiac function.
Physiol Rev. 1998 Oct;78(4):921-47. doi: 10.1152/physrev.1998.78.4.921.
10
Phospholamban regulates the Ca2+-ATPase through intramembrane interactions.
J Biol Chem. 1996 Sep 6;271(36):21726-31. doi: 10.1074/jbc.271.36.21726.
Zotero 插件